ADA-friendly PDF: Pembrolizumab in Early-Stage TNBC

Treatment Guidelines: Pembrolizumab for Early-Stage Triple-Negative Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on August 4, September 3, October 8, 2021, and June 24, 2022 to discuss recommendations for the use of pembrolizumab in patients with early-stage TNBC.